• Càncer
  • Medicina Regenerativa
  • Neurociències
  • Medicina Translacional


After the success of the first edition, a new IDIBELL Accelerator Meeting Point (AMP) will take place next March 5th at IDIBELL.


In this second edition, 9 preselected researchers will have the opportunity to pitch their innovation projects to a panel of valuable experts with the aim to help them bring their technology to society, having a clear vision of the market. The selected projects include new cancer therapies, medical devices, biomarkers and regenerative medicine.


Experts belong to innovation institutions, biotechnology industry and stakeholders interested in healthcare investment . Jury panel will be, among others, formed by Jordi Naval (General Director at Biocat), Melqui Calzado (General Secretary   at CataloniaBio & HealthTech), Michael Tadrós (Innovation Manager at Botín Foundation), Lucas Martinez  (CEO at DCN Ventures); Esther Riambau (Life Sciences Director at UPF Ventures); Ignasi Heras (Investment Analyst at Nina Capital); Georgina Sorrosal (Investment Analyst at Healthequity); Mireia Angulo (Investment Analyst at Caixa Capital Risc); Andrea Sáez (Investment Associate at Asabys Partners); Marc Ramis (Investment Analyst  at life biosciences) and  Beatriz Volckaert (Impact Investment Analyst at Ship2B Foundation).



Este proyecto ha sido financiado con fondos del Ministerio de Ciencia, Innovación y Universidades bajo la convocatoria Redes y Gestores de la Agencia Estatal de Investigación, dentro del Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016 (Importe de la ayuda: 176.324 €. Ref. ECT 2017 – 0322).